Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities ...

Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

With CHMP endorsement in hand, Merck looks to win final marketing authorization from the European Commission in the second quarter of this year, according to a company press release. Already in ...

and there can be no guarantees that the vaccine will receive the necessary regulatory approvals or be commercially successful. In other recent news, Merck & Co. has been at the center of several ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Financial giants have made a conspicuous bearish move on Merck & Co. Our analysis of options history for Merck & Co (NYSE:MRK) revealed 12 unusual trades. Delving into the details, we found 33% of ...